CD40 agonists represent today the novel frontier in the treatment of this carcinoma [32], since CD40 ligation plays an important role also in neo-vascularization of tumors [33] and anti-angiogenesis and immunotherapy represent next-generation approaches in the treatment of renal cell carcinoma [34]. The gene discussed is CD40; the disease is renal cell carcinoma.